These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33643050)

  • 1. Identification and Enzymatic Activity Evaluation of a Novel
    Zhou XY; Lu XR; Li YH; Ma YQ; Zhao SW; Wang F; Xu RA; Hu GX; Cai JP
    Front Pharmacol; 2021; 12():619339. PubMed ID: 33643050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62.
    Chen H; Dai DP; Zhou S; Liu J; Wang SH; Wu HL; Zhou Q; Geng PW; Chong J; Lü Y; Cai JP; Yang JF
    Chem Biol Interact; 2020 Aug; 327():109168. PubMed ID: 32531309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient.
    Luo SB; Li CB; Dai DP; Wang SH; Wang ZH; Geng PW; Cai J; Jiang ZL; Pu CW; Shang K; Yuan XM; Cao YP; Hu GX; Cai JP
    J Pharmacol Sci; 2014; 125(2):150-6. PubMed ID: 25075423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
    Bedewy AML; Sheweita SA; Mostafa MH; Kandil LS
    Indian J Hematol Blood Transfus; 2018 Apr; 34(2):328-336. PubMed ID: 29622878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Identification of a novel CYP2C9 gene mutation (1400T>C) and assessment of its enzymatic activity in vitro].
    Dai DP; Li CB; Wang SH; Geng PW; Hu GX; Cai JP
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3537-41. PubMed ID: 24521898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of 32 CYP2C9 allelic variants.
    Niinuma Y; Saito T; Takahashi M; Tsukada C; Ito M; Hirasawa N; Hiratsuka M
    Pharmacogenomics J; 2014 Apr; 14(2):107-14. PubMed ID: 23752738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
    Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
    Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics aspects of oral anticoagulants therapy.
    Militaru FC; Vesa SC; Pop TR; Buzoianu AD
    J Med Life; 2015; 8(2):171-5. PubMed ID: 25866574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients.
    Jiang NX; Ge JW; Xian YQ; Huang SY; Li YS
    Biomed Rep; 2016 Apr; 4(4):453-458. PubMed ID: 27073631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
    Gulseth MP; Grice GR; Dager WE
    Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population.
    Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A
    Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Assessment of 12 Rare Allelic
    Kumondai M; Ito A; Gutiérrez Rico EM; Hishinuma E; Ueda A; Saito S; Nakayoshi T; Oda A; Tadaka S; Kinoshita K; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33540768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.
    Dai DP; Wang YH; Wang SH; Geng PW; Hu LM; Hu GX; Cai JP
    Acta Pharmacol Sin; 2013 Nov; 34(11):1449-56. PubMed ID: 24077631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.